Table 1.
Characteristics of patients in the US who underwent first AHCT for light chain amyloidosis and reported to the CIBMTR between year 2014 and 2018
| Variable | Bortezomib Induction (n=294) | No Induction (n=146) |
|---|---|---|
| Number of centers | 65 | 37 |
| Median age, years, (range) | 61 (28–78) | 62 (24–77) |
| Male gender | 166 (56) | 82 (56) |
| Race | ||
| White | 250 (85) | 123 (84) |
| Black | 29 (10) | 19 (13) |
| Otherb | 9 (3) | 3 (2) |
| Unknown | 6 (2) | 1 (1) |
| Karnofsky score ≥ 90% | 128 (44) | 72 (49) |
| HCT-CI | ||
| 0 | 54 (18) | 37 (25) |
| 1 | 31 (11) | 19 (13) |
| 2 | 48 (16) | 19 (13) |
| 3+ | 161 (55) | 71 (49) |
| Disease-related | ||
| Cardiac involvement | ||
| Yes | 154 (52) | 71 (49) |
| No | 91 (31) | 58 (40) |
| Missing | 49 (17) | 17 (12) |
| Renal involvement | ||
| Yes | 207 (70) | 105 (72) |
| No | 19 (6) | 19 (13) |
| Missing | 68 (23) | 22 (15) |
| Liver involvement | ||
| Yes | 39 (13) | 15 (10) |
| No | 224 (76) | 127 (87) |
| Missing | 31 (11) | 4 (3) |
| Organ involvement | ||
| 1 | 115 (39) | 57 (39) |
| 2 | 108 (37) | 45 (31) |
| ≥3 | 71 (24) | 44 (30) |
| Serum creatinine at diagnosis ≥2 mg/dl | 37 (13) | 12 (8) |
| Serum albumin at diagnosis, g/dL <3.5 g/dl | 161 (55) | 93 (64) |
| Bone marrow plasma cells at diagnosis ≥10%c | 116 (39) | 16 (11) |
| t(11;14) abnormality present | ||
| No | 203 (69) | 89 (61) |
| Yes | 66 (23) | 35 (24) |
| Test not done/unknown | 24 (8) | 22 (15) |
| Transplant-related | ||
| Time (months) from diagnosis to AHCT, median (range) | 6 (1–9) | 3 (1–9) |
| Center experiencea | ||
| <4 AHCT | 161 (55) | 61(42) |
| ≥4 AHCT | 133 (45) | 85(58) |
| Melphalan Conditioning Dose | ||
| 100 mg/m2 | 40 (14) | 8 (5) |
| 140 mg/m2 | 89 (30) | 36 (25) |
| 180 mg/m2 | 42 (14) | 22 (15) |
| 200 mg/m2 | 123 (42) | 80 (55) |
| No. of CD34 cells infused (x10/kg), range | 3.78 (0.04–12.12) | 4.41 (0.08–12.71) |
| Year of transplant | ||
| 2014 | 7 (16) | 35 (24) |
| 2015 | 63 (21) | 31 (21) |
| 2016 | 77 (26) | 29 (20) |
| 2017 | 65 (22) | 28 (19) |
| 2018 | 42 (14) | 23 (16) |
| Maintenance therapy | ||
| Bortezomib-based | 20 (6) | 12 (8) |
| Lenalidomide-based | 25 (9) | 3 (2) |
| Bortezomib + Lenalidomide | 9 (3) | 6 (4) |
| Other | 7 (2) | 1 (1) |
| No maintenance | 210 (71) | 115 (79) |
| Missing | 23 (8) | 9 (6) |
| Median f/u of survivors | 24.6 (2.3–60.7) | 29.1 (3.4–62.8) |
a
Center experience defined as mean number of AHCT across 4 years from 2015–2018
b
Other race: Asian (n=8); Native American (n=2); More than one race (n=2)
AHCT, autologous hematopoietic cell transplantation; HCT-CI, Hematopoietic cell transplant comorbidity index